The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like peptide-1 (GLP-1) agonists regain the pounds at a steady rate, returning to ...

Retrospective study finds link between blockbuster drugs and longer survival ...

A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction—and help people who already have one, a new study shows.

If you're looking for ways to mitigate your risk of developing cardiovascular disease or experiencing a cardiac event, such as a heart attack or stroke, glucagon-like peptide-1 (GLP-1) ...

Preclinical studies in animals have already shown that GLP-1 drugs can reduce reward-seeking behavior. Early clinical work in humans has begun to hint at similar effects. A randomized trial of ...

Patients with colon cancer using GLP-1 receptor agonists (the class of drugs behind treatments like Ozempic, Wegovy, and Mounjaro) had substantially lower five-year death rates than those not using ...

The World Health Organization (WHO) has finally made its recommendations on using glucagon-like peptide-1 (GLP-1) therapeutics for weight loss, though it remains to be seen whether it changes their ...

New research suggests the weight-loss medications could be powerful tools in tackling substance use disorders.

The popularity of GLP-1 weight-loss medications continues to soar—and their uptake is helping to push down obesity rates on a national scale—but a safe, evidence-based way off the drugs isn’t yet in ...

Popular drugs credited with shrinking waistlines and controlling blood sugar may also take the edge off alcohol’s buzz, according to a new study. Researchers at Virginia Tech's Fralin Biomedical ...

Previously hailed – or derided – as weight-loss aids for the rich and famous, drugs such as Mounjaro, Wegovy and Ozempic took on a far more expansive role in 2025. No longer just considered treatments ...